 |
PDBsum entry 4e05
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase/hydrolase inhibitor
|
PDB id
|
|
|
|
4e05
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Unique thrombin inhibition mechanism by anophelin, An anticoagulant from the malaria vector.
|
 |
|
Authors
|
 |
A.C.Figueiredo,
D.De sanctis,
R.Gutiérrez-Gallego,
T.B.Cereija,
S.Macedo-Ribeiro,
P.Fuentes-Prior,
P.J.Pereira.
|
 |
|
Ref.
|
 |
Proc Natl Acad Sci U S A, 2012,
109,
E3649.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Anopheles mosquitoes are vectors of malaria, a potentially fatal blood disease
affecting half a billion humans worldwide. These blood-feeding insects include
in their antihemostatic arsenal a potent thrombin inhibitor, the flexible and
cysteine-less anophelin. Here, we present a thorough structure-and-function
analysis of thrombin inhibition by anophelin, including the 2.3-Ă… crystal
structure of the human thrombin·anophelin complex. Anophelin residues 32-61 are
well-defined by electron density, completely occupying the long cleft between
the active site and exosite I. However, in striking contrast to substrates, the
D50-R53 anophelin tetrapeptide occupies the active site cleft of the enzyme,
whereas the upstream residues A35-P45 shield the regulatory exosite I, defining
a unique reverse-binding mode of an inhibitor to the target proteinase. The
extensive interactions established, the disruption of thrombin's active site
charge-relay system, and the insertion of residue R53 into the proteinase S(1)
pocket in an orientation opposed to productive substrates explain anophelin's
remarkable specificity and resistance to proteolysis by thrombin. Complementary
biophysical and functional characterization of point mutants and truncated
versions of anophelin unambiguously establish the molecular mechanism of action
of this family of serine proteinase inhibitors (I77). These findings have
implications for the design of novel antithrombotics.
|
 |
|
|
|
|
 |